The Australian Pituitary Foundation have received queries regarding the supply interruption of Minirin Nasal Spray. Please find attached correspondence regarding this from Ferring.
Any patient affected by the interruption of supply should be in contact with their endocrinologist/health provider to explore alternative options including tablets, sublingual wafer or injectables.
“Following our previous communications regarding the interruption in supply of MINIRIN® Nasal Spray and Nasal Drops we now are writing to provide further guidance on the supply situation. Currently there is no stock available for MINIRIN® Nasal Spray and it is anticipated that the available stock of MINIRIN® Nasal Drops will be exhausted by end of October 2020.
Ferring is committed to ensuring that our medicines adhere to the highest quality standards for our patients and an assessment is underway to determine what steps would be needed in order to restart manufacturing. Until the ongoing assessment is concluded and appropriate actions have been implemented, we are unable to estimate a re-start of manufacturing and supply date. At this time, we do not anticipate re-supply of the above MINIRIN®formulations before 2022.
Consequently, all patients who are currently using MINIRIN® Nasal Spray or MINIRIN® Nasal Drops should receive prompt guidance to switch to an alternative treatment. “